Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-01-06 @ 10:20 PM
Study NCT ID:
NCT03363334
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-08-01
First Post:
2017-11-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
Sponsor:
Rigel Pharmaceuticals
Organization:
Study Overview
Official Title:
Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
C-935788-055 is an open-label, multi-center, expanded access (EAP) study.
Detailed Description:
The purpose of the program is to provide Fostamatinib in an Expanded Access setting to subjects who meet the selection criteria.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: